KCAS Bio SAS
keyboard_backspaceBack to Home
Contact
60F Avenue Rockefeller
69008 Lyon
France
Head of Europe Business Development
About us
KCAS Bio is a global bioanalytical laboratory with four main sites: one in Lyon, France (formerly Active Biomarkers), two in the USA (Kansas City, KS, and Philadelphia, PA) and one in the APAC region through an alliance with Crux Biolabs (Melbourne, Australia).
We provide comprehensive and tailored solutions for supporting the development of all modalities, with extensive capabilities and expertise in pharmacokinetics (PK), toxicokinetics (TK), pharmacodynamics (PD), immune profiling, receptor occupancy (ROA), immunogenicity studies (ADA), and biomarker analysis for pre-clinical and clinical studies.
ISO 9001:2015 and GLP accredited, our fully BSL2 test facility in France has a strong track record in developing, qualifying, validating, and implementing bioanalytical and biomarker methods through a wide range of LBA technologies such as ELISA, Luminex, MSD, Ella, Lumipulse and Quanterix. We also support cell & gene therapy programs through our conventional and spectral Flow cytometry and ELISpot capabilities.
Business offer
KCAS Bio provides comprehensive bioanalytical solutions to the global biopharmaceutical industry offering an array of services and technologies:
- PK/TK
- PD/Biomarkers
- Immunogenicity/ADA/Nabs
- Immunophenotyping
- Receptor Occupancy
- Biodistribution
- Dose Formulation Analysis
- Central Lab Services
- Conventional & Spectral Flow Cytometry & Cell Sorting
- Hybrid LC-MS/MS
- LC-MS/MS
- LBA (MSD, ELLA, SimoA, Luminex, ELISA, Lumipulse)
- ELISpot
- Molecular Services (qPCR/ddPCR)
- Cell-based Assay Services
Activities
- Service
- Cardiology
- Genetic Diseases
- Oncology
- Nervous Central System
- Hematology
- Infectiology
- Immunology
- Ophthalmology
- Inflammation
- Immunotherapy lead optimization
- Proof of concept
- Pharmacology potency
- Exploratory toxicology
- in-vitro & ex-vivo models
- Preclinical biomarkers
- Mechanism/Function
- Mechanism of action
- Safety
- PK/PD features
- Indication Identification
- Exploratory toxicology
- Drug-Target interaction
- Level of response duration
- Specificity
- Surrogate markers
- Research exploratory Companion biomarkers
- Animal biomarkers
- Human biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Clinical trials
- Phase I
- Phase II
- Phase III
- Phase IV
- Clinical biomarkers
- Predictive biomarkers
- Treatment efficacy
- Population stratification
- Risk/benefit profile
- Disease progression / follow-up
- Safety
- PK/PD features
- Surrogate markers
- Disease progression monitoring
- Companion biomarkers
- Pharmacology
- Treatment efficacy
- Treatment monitoring
- Toxicity
- Antigen-protective immune-response profile
- Humoral response characterization:
- Antibody dosage
- Functional antibody assays (neutralization, CDC, ADCC)
- Other serological assays
- Cell mediated immunity response
- T cell assays
- Research exploratory biomarkers
- efficiency vaccination
- protection correlation
- Challenge test – Gold Standard
- Induced immune response characterization
- Clinical trials
- Phase I
- Phase II (human challenge trials)
- Phase III (large population pending pathogen prevalence)
